A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma
This study will independently assess the efficacy and safety of two combination therapies
for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor +
dexamethasone + pomalidomide (SdP), selinexor + dexamethasone + bortezomib (SdB), and
selinexor + dexamethasone + lenalidomide (SdL).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society